Vandetanib
As of the edition of 20 October 2026, Vandetanib is a small molecule: marketed, first approved in 2011 (US); acts on EGFR, ERBB2 and ERBB3 and 6 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Caprelsa
- First approved
- 6 April 2011 (US)
- Approvals on record
- 7 in 5 regions
- Holder of the most recent approval
- AstraZeneca; 3 holders in all
- Registered trials
- 102, 24 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Urinary and reproductive; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
10 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product10 company-target rows are on route B because of Vandetanib.
See the 10 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | P07949 |
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| ERBB3 | Receptor tyrosine-protein kinase erbB-3 | P21860 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| ERBB4 | Receptor tyrosine-protein kinase erbB-4 | Q15303 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 0 |
| Phase 1 | 36 | 28 | 0 | 8 |
| Phase 2 | 55 | 35 | 2 | 16 |
| Phase 3 | 7 | 7 | 0 | 0 |
| All trials | 102 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Acquired holder and Lead sponsor of trials | 2002 to now |
| AstraZeneca | Originator and Applicant | 2011 to now |
| Esteve Pharmaceuticals | Applicant | 2012 to now |